Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
| Press Release Montrouge, France, April 5, 2017 |
DBV Technologies to Attend the 10th Kempen Life Sciences Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that Susanna Mesa, Senior Vice President, Strategy, will host investor meetings during the 10th Kempen Life Sciences Conference on Wednesday, April 19, 2017, at the Kempen & Co offices in Amsterdam, Netherlands.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
[email protected]
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
[email protected]
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
[email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/fae7f813-7f1f-41c5-b96f-08b9df9f1ec2
